N
PRME icon

Nuveen’s Prime Medicine PRME Stock Holding History

Nuveen’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$960K Buy
275,931
+24,295
+10% +$92.5K ﹤0.01% 2596
2025
Q4 		$873K Buy
251,636
+25,793
+11% +$115K ﹤0.01% 2677
2025
Q3 		$1.25M Buy
225,843
+17,949
+9% +$72.9K ﹤0.01% 2516
2025
Q2 		$513K Buy
207,894
+148,492
+250% +$229K ﹤0.01% 2883
2025
Q1 		$374K Sell
59,402
-333,041
-85% -$850K ﹤0.01% 2986
2024
Q4 		$1.15M Hold
392,443
– – ﹤0.01% 2658
2024
Q3 		$1.52M Hold
392,443
– – ﹤0.01% 2560
2024
Q2 		$2.02M Buy
392,443
+242,070
+161% +$1.47M ﹤0.01% 2394
2024
Q1 		$1.05M Buy
150,373
+42,280
+39% +$321K ﹤0.01% 2684
2023
Q4 		$958K Buy
108,093
+1,171
+1% +$9.02K ﹤0.01% 2748
2023
Q3 		$1.02M Sell
106,922
-16,273
-13% -$211K ﹤0.01% 2564
2023
Q2 		$1.8M Buy
123,195
+109,067
+772% +$1.52M ﹤0.01% 2400
2023
Q1 		$174K Hold
14,128
– – ﹤0.01% 3007
2022
Q4 		$262K Buy
+14,128
New +$255K ﹤0.01% 3015

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Nuveen's PRME Position: Q1 2026 in Review

Nuveen increased its Prime Medicine (PRME) stake by 9.7% in Q1 2026, buying an estimated $92.5K and bringing the position to 275,931 shares worth $960K. The position accounts for ﹤0.01% of the portfolio, ranked #2596.

Nuveen first reported a position in PRME in Q4 2022 and has held it in 14 quarters since. The position peaked at $2.02M in Q2 2024. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Nuveen held 275,931 shares of Prime Medicine worth $960K as of Q1 2026.
  • Nuveen bought 24,295 Prime Medicine shares in Q1 2026, an estimated $92.5K.
  • Prime Medicine made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #2596 holding.
  • Nuveen first reported a position in Prime Medicine in Q4 2022 and has held it in 14 quarters since.
  • Nuveen's Prime Medicine position peaked at $2.02M in Q2 2024.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.